Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, TSX: EPRX) released updated clinical data from its Phase 1b/2a RESOLVE trial evaluating EP-104GI for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE